Close

BioPharmX (BPMX) Expects Topline Results from Phase 2b Trial of BPX-01 in First Half of May 2017

April 20, 2017 9:28 AM EDT Send to a Friend
BioPharmX Corporation (NYSE: BPMX), a specialty pharmaceutical company developing products for the dermatology market, announced the last subject visit ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login